• 摘要:
      目的  规范头孢他啶-阿维巴坦在多重耐药革兰阴性菌感染治疗中的临床合理应用,为临床实践提供科学指导。
      方法  浙江省医院药事管理质控中心、浙江省药学感染药学专业委员会、浙江省药学会微生物耐药与控制专业委员会以及浙江医学会细菌感染和耐药防治专业委员会联合组织了浙江省临床药学、感染病学和微生物学领域的专家团队。基于循证医学证据和专家意见,经过多轮专家讨论,制定了头孢他啶-阿维巴坦的临床用药指引。
      结果 该指引共包含13个临床问题和28条推荐意见,涵盖了头孢他啶-阿维巴坦的适应证、抗菌谱、用法用量、特殊人群使用、血药浓度监测及临床管理等内容。
      结论 该指引可为临床医生合理使用头孢他啶-阿维巴坦提供科学的指导,有助于提高多重耐药革兰阴性菌感染的治疗效果。

       

      Abstract:
      OBJECTIVE  To standardize the clinical rational use of ceftazidime-avibactam in the treatment of multidrug-resistant Gram-negative bacterial infections and provide scientific guidance for clinical practice.
      METHODS  The Zhejiang Hospital Pharmacy Administration Quality Control Center, Hospital Pharmacy Committee of Zhejiang Pharmaceutical Association, Microbial Resistance and Control Committee of Zhejiang Pharmaceutical Association, Bacterial Infections and Antibiotic Resistance Prevention Committee of Zhejiang Medical Association organized an expert team in the fields of clinical pharmacy, infectious diseases, and microbiology. Based on evidence-based medical evidence and expert opinions, and after multiple rounds of expert discussions, a clinical medication guide for ceftazidime-avibactam was developed.
      RESULTS  The guide includes 13 clinical questions and 28 recommendations, covering aspects such as indications, antimicrobial spectrum, dosage and administration, use in special populations, therapeutic drug monitoring, and clinical management of ceftazidime-avibactam.
      CONCLUSION  The guidelines can provide scientific guidance for the rational use of ceftazidime-avibactam by clinicians, and improve the treatment outcomes of multidrug-resistant Gram-negative bacterial infections.

       

    /

    返回文章
    返回